From 2016 to 2023, the share of HIV-positive tuberculosis patients on antiretroviral therapy in Argentina demonstrated fluctuating trends, with noticeable volatility in the early years and stabilizing variations in the most recent years. From a low of 4.7 units in 2019, the share surged dramatically to 99 units in 2020, creating an outlier year. By 2023, it had normalized to 37.5 units. The year-on-year decrease from 2022 to 2023 was 1.05%, and over the last two years, the decline was due to market stabilization. The CAGR over the last five years stands at -0.32%, indicating a gradual annual decrease.
Future trends to watch for include potential advancements in treatment protocols and healthcare policies aimed at HIV and tuberculosis co-infections. A close watch on the integration of healthcare services and the impact of new antiretroviral drugs will be crucial in shaping future outcomes. Additionally, monitoring socio-economic factors that influence healthcare access may provide insights into further trend developments.
